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cytes RA depletion resulted on encouraging results, with a very
low incidence of acute and chronic GVHD, but preserving the
GVL effect by infusing CD45 RA- donor lymphocytes.
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Introduction: High dose post-transplant cyclophosphamide
has improved the outcomes and expanded the use of haploi-
dentical hematopoietic cell transplantation (haplo-HCT). The
impact of HLA disparity in this setting, however, is unclear and
is traditionally measured at the antigen or allele level. The Pre-
dicted Indirectly Recognizable HLA Epitopes (PIRCHES) model
provides a novel tool to calculate the number of mismatched
HLA peptides between donor and host that can be processed
and presented by shared HLA antigens for T cell recognition.
No data exist on the relationship between PIRCHES mismatch
and clinical outcome in haplo-HCT with post-transplant
cyclophosphamide.
Methods: 148 patients who received a peripheral blood, T-cell
replete haplo-HCT with post-transplant cyclophosphamide at
a single center between 2009 and 2016 were retrospectively
analyzed. The PIRCHES mismatch load was calculated using
the PIRCHES matching tool online and was categorized by class
and vector. The primary outcome was incidence of relapse. The
association between PIRCHES mismatch and outcome was ana-
lyzed using the Cox proportional hazard model or Gray’s sub-
distribution method for competing risk as appropriate. This
study was approved by the Institutional Review Board.
Results: The median follow-up for survivors was 34.0 months
(range, 14.5-78.3 months). One-hundred (67.6%) patients were
deceased and 61 (41.2%) patients relapsed during follow-up.
Class I graft-versus-host (GvH) PIRCHES mismatch had a
median of 11 with a range of 0 to 56. Class II GvH PIRCHES mis-
match had a median of 29 with a range of 0 to 122. Class I GvH
PIRCHES mismatch was associated with worse acute graft-ver-
sus-host disease (aGvHD) (grades II-IV) (HR 1.021 per unit
PIRCHES mismatch increase; 95% CI 1.001-1.040; p=0.036).
Class I GvH PIRCHES mismatch was not associated with treat-
ment-related mortality (TRM), but was associated with a trend
towards worsened overall survival (OS) (HR 1.015 per unit
PIRCHES mismatch increase; 95% CI 0.999-1.033; p=0.073).
Class I host-versus-graft (HvG) PIRCHES mismatch was associ-
ated with worse relapse-free survival (RFS) (HR 1.018; 95% CI1.001-1.035; p=0.036) and worse OS (HR 1.018; 95% CI 1.001-
1.035; p=0.036) but not relapse. Class II PIRCHES mismatch
was not associated with relapse, OS, RFS, TRM, or aGvHD. Both
class I and II PIRCHES mismatch were not associated with
chronic GvHD or engraftment.
Discussion: Class I GvH PIRCHES mismatch was associated
with greater aGvHD and a trend towards worsened OS, while
class I HvG PIRCHES mismatch was associated with worsened
RFS and OS. Class II PIRCHES mismatch was not associated
with outcomes and appears to be tolerated by this patient
cohort. PIRCHES mismatch represents a novel strategy to pre-
dict clinical outcome in haplo-HCT. Further studies using regis-
try data and prospective studies are needed to validate these
findings.290
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Introduction: The preapheresis peripheral blood CD34+ cell
count (PBCD34) is the most important predictor of a good
mobilization. Flow cytometry is not always immediately avail-
able in our country, therefore looking for another surrogate
marker to predict CD34+ counts would be useful. Lactate dehy-
drogenase (LDH) has been correlated to higher PCBCD34.
Objective: We aim to investigate if LDH difference is a reliable
tool to predict a poor mobilization in our patients.
Methods: We included all patients who receive an autologous
transplant from January 2015 to September 2018. Demo-
graphic and laboratory characteristics were obtained, includ-
ing complete blood count, preapheresis PBCD34 and DHL
(table 1). Poor mobilization was defined as a final PBCD34+
count <2£ 106/kg. The association between these parameters
was assessed, Spearmans correlation was used and ROC curves
calculated.
Results: Seventy four patients were included. Median age was
43 years (11-72 years), 48% female, diagnosis were 31 mye-
loma multiple, 19 non Hodgkin lymphoma, 7 Hodgkin disease,
17 others. An adequate yield of CD34+ cells/kg was collected in
64 patients (86%). Preapheresis PBCD34+ had a stronger corre-
lation with the difference of recollection minus basal LDH
(Rho = 0.44, p = 0.001) than with monocytes (Rho = 0.189,
p = 0.119). The area under the curve for LDH difference was
0.83 (p = 0.001, CI95% 0.72-0.95) (figure 1).
Conclusion: LDH difference is a good predictor of poor mobili-
zation, with the main advantage that is a fast, cheap and easy
marker to perform. It would be useful particularly in centers
with poor access to flow cytometry or where the CD34+ count
is delayed.
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Safety and efficacy of alloreactive T-cell depletion performed ex vivo (ATIR101)
after T-cell-depleted haplo-HSCT versus in vivo (PTCy) after T-cell-replete
haplo-HSCT291
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Introduction: In haploidentical allogeneic hematopoietic stem
cell transplantation (haplo-HSCT), different strategies are used
to eliminate alloreactive T cells, one of which can be performed
in vivo early after T-cell-replete haplo-HSCT using post-trans-
plant cyclophosphamide (PTCy). Currently under development
is T-cell-depleted haplo-HSCT supplemented with T-lympho-
cytes that are depleted ex vivo of their alloreactive component
(ATIR101; Kiadis Pharma). Both strategies are promising, but
comparisons of clinical outcomes obtained in similar patient
populations have not been performed.
Methods: Data from published retrospective studies were ana-
lyzed to assess clinical outcomes of haplo-HSCT plus PTCy, and
1-year outcomes were compared with a pooled analysis of 2
phase II clinical trials of a single dose of ATIR101 in 37 AML/
MDS/ALL patients. Studies in which PTCy was used in patient
populations with >50% AML/MDS/ALL were identified (Table).
The 1-year rates of relapse, relapse-related mortality (RRM),
non-relapse mortality (NRM), graft-versus-host disease
(GVHD), and overall survival (OS) for the ATIR101 clinical trials
were compared with the weighted average of these outcomes
for the identified studies. Differences in disease risk index
(DRI) between PTCy and ATIR101 study populations were
adjusted according to the relationship between DRI and OS.
Finally, PTCy studies reporting GVHD-free and relapse-free
survival (GRFS) were identified. One-year GRFS rates from 2
haplo-HSCT plus PTCy studies reporting DRI status were also
normalized according to the DRI profile in the ATIR101 clinical
trials to allow comparison.
Results: The weighted average of PTCy outcomes in popula-
tions with >50% AML/MDS/ALL vs ATIR101 patient outcomes
were 29% vs 8% for relapse; 18% vs 8% for RRM; 22% vs 33% for
NRM; 5% vs 5% for acute GVHD grade III/IV; 24% vs 3% for
chronic GVHD; and 60% vs 58% for OS. The OS in DRI-adjusted
studies for PTCy was similar to that in ATIR101 clinical trials
(63% vs 58%, respectively, Table). One-year GRFS rates for PTCy
were 33% (95% CI: 2541) (Solh 2016), 45% (95% CI: 4050)
(McCurdy 2017), and 33% (average) (Santoro 2017). The DRI
profile was more favorable than in the ATIR101 studies and
the normalized 1-year GRFS rates were reduced to 30% (Solh
2016) and 40% (McCurdy 2017). In patients intended to receive
a single dose of ATIR101 after haplo-HSCT, 1-year GRFS esti-
mate was 53% (95% CI 3972).Conclusion: Although not a head-to-head comparison, these
cross-study analyses provide first insights into a potential
advantage of ex vivo (ATIR101) over in vivo (PTCy) depletion of
alloreactive T cells, including but not limited to rates of relapse,
chronic GVHD, and GRFS. A large, phase III, randomized control
trial is underway to assess the relative safety and efficacy of
ATIR101 after T-cell-depleted haplo-HSCT versus PTCy after T-
cell-replete haplo-HSCT (CR-AIR-009 HATCY; NCT02999854).292
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